Identifying new treatments for liver scarring is “critical” to tackling the epidemic of liver disease. More: "Molecular profiling" could be key to new liver disease treatments Source: News
read moreThe proposed improvement could cut costs and save patients avoidable trips to their GP. More: Refining blood tests could help detect heart failure Source: News
read moreWith global recalls of heart burn med Zantac ongoing, the FDA is hoping to restore consumer confidence. Worried about higher-than-recommended levels of a possible carcinogen in the pills? They’re no more dangerous than a grilled ribeye, the agency said Monday. More: FDA: Zantac carcinogens
read moreIndia’s Zydus group began steps to fix its perpetually troubled sterile manufacturing plant in Moraiya as soon as an FDA inspector uncovered manufacturing issues this spring. Its efforts failed to do the job. More: Zydus Cadila injectables plant slapped with FDA warning letter over contamination
read moreSince Allergan’s Namenda approval in late 2003, the world hasn’t seen a new Alzheimer’s drug for 17 years. That drought was broken Saturday, not by a Western biopharma bigwig with a U.S. approval, but a little-known Chinese firm with a
read moreWhen Sanofi bought Genzyme in 2011, Lemtrada was only a promising multiple sclerosis drug candidate, so the French drugmaker promised the biotech’s shareholders future payments if the med hit particular goals. Years later, those investors claimed Sanofi dragged its feet
read more© 1994 - 2026 B.M. Pharmaceuticals